NCT07258836 2026-04-17
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
Eli Lilly and Company
Phase 1 Recruiting
Clinical Trials
1,020 trialsNCT06959706 2026-04-16
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Tagworks Pharmaceuticals BV
Phase 1 Recruiting
NCT01481532 2026-04-15
Open Label Clinical Trial of Intravenous Crotoxin Part 3
Celtic Biotech Ltd
Phase 1 Not yet recruiting
NCT07532018 2026-04-15
DXP-106
Singlomics (Beijing DanXu) Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT04958239 2026-04-14
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT05382559 2026-04-14
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT06150157 2026-04-14
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT04606381 2026-04-13
PALOMA
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06178614 2026-04-13
A Study of JNJ-87890387 for Advanced Solid Tumors
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07247110 2026-04-13
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT07525141 2026-04-13
A Study of JNJ-1761981 in Participants With Solid Tumors
Johnson & Johnson Enterprise Innovation Inc.
Phase 1 Not yet recruiting
NCT06555744 2026-04-09
A Study of ZW191 in Participants With Solid Tumors
Zymeworks BC Inc.
Phase 1 Recruiting
NCT03366116 2026-04-08
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06997029 2026-04-07
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Recruiting
NCT01445509 2026-04-06
Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT07438782 2026-04-06
First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Recruiting
NCT07144085 2026-04-03
Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.
First Hospital of China Medical University
Phase 1 Recruiting
NCT02379416 2026-04-01
Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03449381 2026-03-31
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Completed
NCT05887882 2026-03-30
PNOC028
University of California, San Francisco
Phase 1 Recruiting
NCT06188208 2026-03-30
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
Vividion Therapeutics, Inc.
Phase 1 Terminated
NCT06884618 2026-03-30
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
Hoffmann-La Roche
Phase 1 Recruiting
NCT03568058 2026-03-24
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
University of California, San Diego
Phase 1 Completed
NCT04443088 2026-03-18
KEYNOTE-E12
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1 Recruiting
NCT05719558 2026-03-18
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT06298357 2026-03-18
Virtual Reality Gaming for Exercise and Mindfulness Among Pediatric Cancer Rehabilitation
University of Alabama at Birmingham
Phase 1 Completed
NCT01374620 2026-03-16
PAL-ANGI2
Centre Oscar Lambret
Phase 1 Completed
NCT07030712 2026-03-16
MK-8294-001
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT07474168 2026-03-16
T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
Zhejiang University
Phase 1 Active not recruiting
NCT07454031 2026-03-13
Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma
Peking University
Phase 1 Not yet recruiting
NCT05707910 2026-03-09
Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors
West China Hospital
Phase 1 Active not recruiting
NCT02423057 2026-03-06
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT06713369 2026-03-04
AZD5305
AstraZeneca
Phase 1 Recruiting
NCT03391778 2026-03-03
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
USWM, LLC (dba US WorldMeds)
Phase 1 Recruiting
NCT07046559 2026-03-03
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants
Eli Lilly and Company
Phase 1 Recruiting
NCT06759649 2026-02-27
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
Compugen Ltd
Phase 1 Recruiting
NCT03203525 2026-02-25
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT07156136 2026-02-25
Study of IMC-P115C in Advanced PRAME-Positive Cancers
Immunocore Ltd
Phase 1 Recruiting
NCT03964233 2026-02-18
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
Boehringer Ingelheim
Phase 1 Completed
NCT06524570 2026-02-18
iFOCUS
UMC Utrecht
Phase 1 Recruiting
NCT06311578 2026-02-13
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Johnson & Johnson Enterprise Innovation Inc.
Phase 1 Recruiting
NCT01534598 2026-02-10
FdCyd and THU for Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT06607939 2026-02-10
OR2-01
Orionis Biosciences Inc
Phase 1 Recruiting
NCT06717750 2026-02-02
A Study of CSCJC3456 in Patients With Advanced Malignant Tumors
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
Phase 1 Recruiting
NCT02952248 2026-01-27
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT07368127 2026-01-26
A Study of TPD3310 in Patients With Advanced Malignant Tumors
TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.
Phase 1 Not yet recruiting
NCT07348042 2026-01-16
Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors
Fudan University
Phase 1 Recruiting
NCT07292038 2026-01-14
Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors
NucMito Pharmaceuticals Co. Ltd.
Phase 1 Recruiting
NCT05273554 2026-01-12
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05270213 2025-12-19
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Riboscience, LLC.
Phase 1 Recruiting